<DOC>
	<DOCNO>NCT00120302</DOCNO>
	<brief_summary>This study conduct US . The study consist 4 week double blind treatment period . All patient meet inclusion/exclusion criterion enter study day 0 randomize either pimecrolimus cream 1 % vehicle treatment group 1:1 ratio . Patients return clinic day 7,14 28 assessment disease severity . Patients experience unsatisfactory therapeutic effect , attend unscheduled visit withdrawn study . Assessments eligibility include Investigator 's Global Assessment Pruritus score . Treatment history collect baseline Quality Life Questionnaires carry every visit .</brief_summary>
	<brief_title>Quality Life Study Adults With Facial Eczema</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Males female age 18 year older Active Moderate Facial AE baseline ( Facial IGA score 3 ) , within 3 day deterioration symptom necessitate treatment . Diagnosis AE fulfil diagnostic criterion Williams ( Williams , et al . 1994 ) outline : *Must itchy skin condition plus 3 follow 5 item list : 1 . History involvement skin crease fold elbow , behind knee , front ankles around neck ; 2 . A personal history asthma hay fever ; 3 . A history general dry skin last year ; 4 . Visible flexural edema ; 5 . Onset age 2 Pruritus score 2 baseline Patients use TCS clinically inappropriate due : burning , sting , allergic reaction adverse event prevents patient use topical corticosteroid successfully treat AE flare face ; presence rosacea , telangiectasia , skin atrophy glaucoma result topical corticosteroid usage face ; presence AE eyelid Or patient previous treatment unsatisfactory would prefer try alternative treatment option . Patients inform study procedure sign informed consent form approve study . ( Informed consent sign instruct ICHGCP local regulation ) . At baseline throughout study , female childbearing potential : Who pregnant breastfeed Who menstruating , capable become pregnant , practice medically approve method contraception least 4 week end study treatment . A negative pregnancy test ( urine ) females childbearing potential require screening visit . 'Medically approve ' contraception may include abstinence discretion investigator At baseline throughout study , patient : Who receive phototherapy ( e.g . UVB , UVA ) systemic therapy ( e.g . immunosuppressant , cytostatics ) know suspected effect AE within 1 month Visit 1 ( baseline ) Who receive systemic corticosteroid ( e.g . oral , intravenous , intraarticular , rectal ) within 1 month Visit 1 . Patients stable maintenance dose inhaled corticosteroid may participate Who known suspect contact allergic dermatitis Who receive systemic antibiotic within 2 week prior Visit 1. Who use oral topical antihistamine treatment Pruritus within 2 week prior visit 1 Who apply topical therapy ( e.g . tar , topical corticosteroid , pimecrolimus tacrolimus within 2 week prior Screening Who use potent potent TCS within 4 week prior Visit 1. Who immunocompromised ( e.g . lymphoma , HIV infection/AIDS , WiskottAldrich Syndrome ) history malignant disease Who history poor clinical response , hypersensitivity topical pimecrolimus cream 1 % . Who concurrent skin disease ( e.g . acne ) severity study area could interfere evaluation . Who active bacterial ( e.g . impetigo ) , viral ( e.g . chicken pox , herpes simplex ) fungal infection ( e.g . tinea corporis , intertriginosa ) Who receive investigational drug within 8 week visit 1 , plan use investigational drug course study Who , opinion investigator , know unreliable , noncompliant medical treatment , know miss appointment Who abuse problem , mental dysfunction factor limit ability cooperate fully studyrelated procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Randomised</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Elidel</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Atopic Eczema</keyword>
</DOC>